Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Councilor Viewpoints

Add a description of this content here 

test


test
More
Close

Biologics

Choosing the most appropriate first line biologic

Biologics 2020

Richard Warren, BSc, MBChB, FRCP, PhD | United Kingdom

More
Close

How to select a systemic treatment for your patient

Biologics 2020

Craig Leonardi, MD | United States

More
Close

Challenging case: How to switch to the most optimal treatment

Biologics, Challenging case 2020

Craig Leonardi, MD | United States

More
Close

Management of psoriasis with biologics during the COVID-19 pandemic – Italian

Biologics, COVID-19, Take Ten 2020

Paolo Gisondi, MD | Italy

More
Close

Biologics: Modification strategies

Biologics, Take Ten 2021

Marc Bourcier, MD, FRCPC | Canada

More
Close

Biologics: Dose optimization

Biologics, Take Ten 2021

Marc Bourcier, MD, FRCPC | Canada

More
Close

Caso Clínico 2: Psoriasis paradojal inducida por anti-TNF

Biologics, Challenging case, Spanish 2021

Romina Contreras, MD | Paraguay

More
Close

Search Reviews:

Filter by Topic:


Latest news

May 26, 2022
Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.
May 16, 2022
Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.
May 11, 2022
IPC Councilor, Ulrich Mrowietz, MD, shares his expert opinion on Cook et al (Br J Dermatol 2022 (online first)) report on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis.
May 03, 2022
IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!
More News
We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK